We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+51.05%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$154M
AUM Growth
-$23.7M
Cap. Flow
-$63.9M
Cap. Flow %
-41.49%
Top 10 Hldgs %
62.2%
Holding
45
New
6
Increased
7
Reduced
17
Closed
12

Top Buys

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$9.41M
2
ELVN icon
Enliven Therapeutics
ELVN
+$4.18M
3
CLDX icon
Celldex Therapeutics
CLDX
+$1.63M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$1.48M
5
MREO
Mereo BioPharma
MREO
+$1.35M

Top Sells

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$23.5M
2
KURA icon
Kura Oncology
KURA
+$11.9M
3
CBAY
Cymabay Therapeutics
CBAY
+$11.6M
4
EYPT icon
EyePoint Inc
EYPT
+$9.82M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$6.16M

Sector Composition

Rank Sector Weight
1 Healthcare 99.37%
2 Financials 0.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORIC icon
26
Oric Pharmaceuticals
ORIC
$1.34B
$1.43M 0.93%
+103,992
New +$1.24M
MREO
27
Mereo BioPharma
MREO
$48.8M
$1.31M 0.85%
+397,884
New +$1.35M
LYRA
28
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.08M 0.7%
+3,466
New +$923K
CYPH
29
Cypherpunk Technologies Inc
CYPH
$71.7M
$942K 0.61%
354,166
– –
RARE icon
30
Ultragenyx Pharmaceutical
RARE
$2.55B
$934K 0.61%
+20,000
New +$943K
ITCI
31
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$920K 0.6%
+13,300
New +$914K
CLRB icon
32
Cellectar Biosciences
CLRB
$20.1M
$571K 0.37%
4,783
-11,134
-70% -$1.21M
NUVB.WS
33
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$27.5K 0.02%
90,832
– –
ANTX icon
34
AN2 Therapeutics
ANTX
$219M
– –
-132,000
Closed -$2.7M
APLS
35
DELISTED
Apellis Pharmaceuticals
APLS
– –
-76,100
Closed -$4.56M
ARGX icon
36
argenx
ARGX
$54.8B
– –
-2,400
Closed -$913K
AVXL icon
37
PUT
Anavex Life Sciences
AVXL
$304M
– –
-1,000
Closed -$22.5K
CNTA
38
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-38,138
Closed -$304K
EYPT icon
39
EyePoint Inc
EYPT
$1.11B
– –
-425,128
Closed -$9.82M
FDMT icon
40
4D Molecular Therapeutics
FDMT
$552M
– –
-74,500
Closed -$1.51M
SWTX
41
DELISTED
SpringWorks Therapeutics
SWTX
– –
-10,000
Closed -$365K
TYRA icon
42
Tyra Biosciences
TYRA
$1.61B
– –
-8,867
Closed -$123K
VRNA
43
DELISTED
Verona Pharma
VRNA
– –
-19,000
Closed -$378K
CBAY
44
DELISTED
Cymabay Therapeutics
CBAY
– –
-492,155
Closed -$11.6M
RYZB
45
DELISTED
RayzeBio, Inc. Common Stock
RYZB
– –
-378,069
Closed -$23.5M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return

Acuta Capital Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Acuta Capital Partners held 45 positions worth $154M, down 13% from $178M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Acuta Capital Partners withdrew a net $63.9M in Q1 2024, closing 12 positions and reducing 17 holdings. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $23.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Agios Pharmaceuticals worth $1.62M.

  • Acuta Capital Partners's largest Q1 2024 buy was Agios Pharmaceuticals: 55,262 shares worth $1.62M.
  • Acuta Capital Partners added most to Ocular Therapeutix in Q1 2024, an estimated $9.41M increase.
  • Acuta Capital Partners's biggest Q1 2024 reduction was Kura Oncology, cutting an estimated $11.9M.
  • Acuta Capital Partners fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $23.5M.
  • Acuta Capital Partners's ten largest holdings make up 62% of its $154M portfolio in Q1 2024.
  • Acuta Capital Partners opened 6 new positions and closed 12 in Q1 2024.
  • Acuta Capital Partners's portfolio value fell 13% quarter-over-quarter to $154M.

Based on Acuta Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.